CLAIMS

1. Use of an effective amount of an alkalizing agent that increases the intracellular pH of a host cell and/or of an intracellular compartment of a host cell and an effective amount of a bactericidal agent in the manufacture of a medicament for the treatment of a bacterial infection in a subject in need thereof, wherein the bactericidal agent is selected from the group consisting of a subclass IIIa bacteriocin, a bacterial autolysin and a bacteriophage lysin.

2. The use according to claim 1, wherein the bacterial infection is an intracellular and/or persistent bacterial infection and/or is a *Staphylococcus* infection, preferably an *S. aureus* infection.

3. The use according to claim 1 or 2, wherein the host cell is a eukaryotic host cell within the subject in need of treatment and/or wherein the intracellular compartment is a phagolysosome.

4. The use according to any of the preceding claims, wherein the agent that increases the intracellular pH and/or the pH of the intracellular compartment is , a lysosomotropic alkalizing agent, preferably selected from the group of chloroquine, bafilomycin A1, ammonium chloride.

5. The use according to any of the preceding claims, wherein the bactericidal agent is a bactericidal agent capable of entering the host cell and/or the intracellular compartment of the host cell.

6. The use according to claim 1 to 5, wherein the bactericidal agent comprises a functional enzymatic domain from a cell wall lytic enzyme and preferably further comprises a protein transduction domain.

7. The use according to claim 6, wherein the bactericidal agent further comprises an antimicrobial peptide.

8. The use according to claim 6 or 7, wherein the bactericidal agent further comprises a cell wall binding domain.

9. The use according to claim 6 - 8, wherein the protein transduction domain is selected from the group consisting of SEQ ID NO: 12 - 25.

10. The use according to claim 6 - 9, wherein the functional enzymatic domain from a cell wall lytic enzyme is selected from the group consisting of SEQ ID NO: 1 - 7.

11. The use according to claim 8 - 10, wherein the cell wall binding domain is selected from the group consisting of SEQ ID NO: 8 - 11.

12. The use according to claim 7 - 11, wherein the antimicrobial peptide is selected from the group consisting of SEQ ID NO: 70 - 90.

13. A chimeric bactericidal polypeptide comprising a functional enzymatic domain from a cell wall lytic enzyme selected from the group consisting of SEQ ID NO: 1 - 7 and a protein transduction domain selected from the group consisting of SEQ ID NO: 12 - 25 and optionally comprising a cell wall binding domain is selected from the group consisting of SEQ ID NO: 8 - 11 and/or an antimicrobial peptide selected from the group consisting of SEQ ID NO: 70 - 90.

14. A chimeric bactericidal polypeptide according to claim 13, wherein the bactericidal agent has at least 80% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 27 – 28, 30 - 47 while maintaining its bactericidal activity, or is a bactericidal agent encoded by polynucleotide sequence with at least 80% sequence identity with a sequence selected from the group consisting of SEQ ID NO: 50 – 67 while maintaining its bactericidal activity.

15. A polynucleotide encoding the chimeric bactericidal polypeptide according to claim 13.